RESUMO
Objective: To study the clinical efficacy of Yangxindingji capsule combined with metoprolol in patients with coronary heart disease complicated with rapid arrhythmia. Methods: A total of 86 cases of patients with coronary heart disease complicated with tachyarrhythmia diagnosed in our hospital from January 2017 to December 2017 were selected as the subjects of this study. All the patients were divided into a control group and a study group according to the principle of the random number table, with 43 cases in each group. The patients in the control group were received oral metoprolol for treatment, and the patients in the study group were treated with oral Yangxindingji capsule combined with Metoprolol for treatment. The treatment effect and the change of heart function and blood rheology were compared between the two groups before and after the treatment. Results: The total effective rate of treatment in the study group was 83.7％ (36/43), which was higher than that in the control group (67.4％ ) (29/43). The difference was statistically significant (P ＜ 0.05); After the treatment, the HR levels in both groups were lower than before treatment, and the study group was lower than the control group, with a significant difference (P ＜ 0.05); The LVEF levels after treatment in the two groups were higher than before treatment, and the study group was higher than the control group. The difference was statistically significant (P ＜ 0.05); The fibrinogen, high-cutting whole blood viscosity, plasma viscosity, and low-cut whole blood viscosity of the two groups after treatment were lower than before treatment, and the study group was lower than the control group. The difference was statistically significant (P ＜ 0.05). Conclusion: Yangxindingji capsule combined with metoprolol has significant effects on coronary heart disease combined with rapid arrhythmia, which can effectively relieve clinical symptoms, improve cardiac function, regulate hemorheology, correct arrhythmia, and is worthy of clinical promotion.